Please login to the form below

Not currently logged in
Email:
Password:

The Saatchi & Saatchi Award for Launch Excellence

Sponsored by

Back to Results


Finalist

VOTRIENT: Lighting the way forward

by GSK with support from PAN


Summary of work

Votrient is the first agent to establish confidence in the treatment of second-line advanced soft tissue sarcoma (aSTS), by demonstrating significant improvement in efficacy across multiple subtypes.

Soft tissue sarcomas are a rare, niche, heterogeneous tumour type with over 50 different subtypes and GSK’s communication campaign captured the essence of this. In an area that is difficult to conduct clinical trials, innovation in study design led to delivering quality Level One evidence, which resonated with the target audience and articulated the key benefits.

GSK worked closely with internal and external stakeholders to deliver a truly comprehensive global campaign with buy-in from all major local operating companies, which communicated the benefits of Votrient in this area of high unmet medical need. The launch campaign success exceeded expectations, with all key objectives being met:

  • Actual sales significantly above plan
  • Barriers to physician and patient access minimised through a detailed payer strategy, resulting in a high number of reimbursed markets at launch
  • Consistent implementation of the global strategy and campaign across markets including the US, in GSK’s first truly global campaign.

Judges comments

This was an innovative, global launch campaign that was solidly executed. It demonstrated good customer insight, positioning, impactful payer strategy and delivered measurable outcomes, overachieving on objectives.



Highly commended

Dificlir Launch Excellence - by Astellas with support from OPEN Health


Finalists

VOTRIENT: Lighting the way forward - by GSK with support from PAN

Hepatitis C - by Janssen with support from Havas Lynx and McCann Health

Zytiga - by Janssen with support from Havas Lynx